Better Health. Better Life.


Scientific Publication Highlights - emosquito-logo

Electronic Mosquito: designing a semi-invasive Microsystem for blood sampling, analysis and drug delivery applications
Gattiker GE., Kaler K., Mintchev MP.
Microsystem Technology, 2005, 12:44-51
Microactuation of suspended MEMS beams
Gattiker G. ; Electr. & Comput. Eng. Dept., Calgary Univ., Alta., Canada ; Kaler K, V.I.S. ; Mintchev, MP.
IEEE Int Symposium on Circuits and Systems,  ISCAS, 2005, May 23-26, Vol 3:2755-2758
Wireless communication and control system for portable microelectromechanical device for real-time blood sampling and glucoseanalysis (electronic mosquito)
Jones TD., Kaler K., Fattouche M., Mintchev MP.
International Journal of Information Technology & Knowledge, 2009, 3:223-231
Characterization of A Cuff-Based Shape Memory Alloy (SMA) Actuator
Wang G, Poscente MD, Park SS, Yadid-Pecht O, Mintchev MP.
International Journal of Information Theories & Applications, 2015, 22(1):3-20

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.